Cargando…
CETP and SGLT2 inhibitor combination therapy improves glycemic control
IMPORTANCE: Cholesteryl ester transfer protein (CETP) inhibition has been associated with decreased risk of new-onset diabetes in past clinical trials exploring their efficacy in cardiovascular disease and can potentially be repurposed to treat metabolic disease. Notably, as an oral drug it can pote...
Autores principales: | Khomtchouk, Bohdan B., Sun, Patrick, Ditmarsch, Marc, Kastelein, John J.P., Davidson, Michael H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312876/ https://www.ncbi.nlm.nih.gov/pubmed/37398493 http://dx.doi.org/10.1101/2023.06.13.23291357 |
Ejemplares similares
-
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
por: Dangas, Katerina, et al.
Publicado: (2022) -
Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021) -
Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors
por: Mabuchi, Hiroshi, et al.
Publicado: (2014) -
Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021) -
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition
por: Martin, Seth S, et al.
Publicado: (2022)